INTRODUCTION
The sex steroid hormones oestrogen and progesterone, in association with peptide hormones and growth factors, play a central role in normal mammary gland development including the control of differentiated function. There is also compelling evidence that oestrogen is intimately involved in the pathogenesis of breast cancer (Henderson et al. 1988 ). The majority of breast carcinomas retain some degree of steroid responsiveness and this has been exploited therapeutically by the use of agents which interfere with the production or action of oestrogenic steroids e.g. aromatase inhibitors, LH-RH agonists, and antioestrogens (Santen et al. 1990 ). Tamoxifen, a Oestrogens are mitogenic for several cell types including epithelial cells of the mammary gland, uterus, and vagina. Early studies in which these mod¬ els were employed revealed that oestrogens increased the rate of cell proliferation both by recruiting noncycling cells into the cell cycle and by shortening the overall cell cycle time, due predomi¬ nantly to a reduction in the length of G! phase (Sutherland et al. 1983c) . Later experiments in which synchronised breast cancer cells were used in vitro confirmed that oestrogen acts in the early part of Gj phase (Leung & Potter 1987) .
Studies with antioestrogens support this conclu¬ sion. Antioestrogen treatment of breast cancer cells in vitro leads to growth arrest, with accumulation of cells in G! phase (Sutherland et al. 1983 , 19836 (Baserga 1990 (Fig. 4) Figure 4 Cell cycle phase-specific gene expression after growth factor stimu¬ lation. T-47D cells were growth arrested in chemically defined serum-free medium then stimulated to reenter the cell cycle by addition of 10pg/ml insu¬ lin at time 0, as in Fig. 1 (Fig. 6) . The decrease was similar in magnitude (50-60%) to the decrease in DNA synthesis as assessed by histone H4 expression and S phase , Watts et al. 1994 . Cyclin Dl expression began to decrease within 4h of antiestrogen treatment, substantially preceding any decline in DNA synthesis (Fig. 6) . Thus, the regulation of cyclin Dl expression by ICI 164384 is not merely a consequence of growth arrest.
Changes in cell cycle phase distribution occur over a similar time frame after antioestrogen or antiprogestin treatment (Musgrove & Sutherland 19936) , and both inhibitors rapidly and profoundly decrease c-myc expression (Fig. 6) . However, clear differ¬ ences in the regulation of Gi cyclin genes were observed after treatment with these compounds. Whereas cyclin Dl expression decreased after antioestrogen treatment, the antiprogestin failed to affect the expression of this gene (Fig. 6) . In contrast, cyclin D3 expression, which was unaffected by antioestrogen treatment, was markedly decreased by antiprogestin treatment to <50% of control (Mus¬ grove et al. 1993 ). This decrease was apparently coincident with the decrease in DNA synthesis (Fig.  6) . Inhibition of cyclin Dl expression accompanies inhibition of cell proliferation by a variety of agents, including tumour necrosis factor oc, interferon , 8-Br-cAMP, and antioestrogens (Cocks et al. 1992 , Watts et al. 1994 suggesting that mechanisms for the regulation of proliferation often, but not invariably, converge on this gene.
In conclusion, these data demonstrate the sequen¬ tial induction of cyclin genes after mitogenic stimulation of breast cancer cells, a phenomenon shared by many other cell types. More importantly, cyclin Dl was the first Gi cyclin to be induced and the level of induction correlated closely with subse¬ quent entry into S phase ), as might be expected given recent evidence for a key role for cyclin Dl in determining the rate and magni¬ tude of cell cycle progression in these cells (Musgrove et al. 1994 (Musgrove et al. 1994 ) and a rapid decline in cyclin Dl mRNA levels after antioestro¬ gen treatment of breast cancer cells , Watts et al. 1994 
